Vaxart was served a grand jury subpoena in July over its controversial role in OWS-funded preclinical study
One-time penny stock player Vaxart made market waves Tuesday morning when the company announced it had dosed the first patients in the Phase I …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
